61 clinical trials
grid
list
download
| Body (indexed field) | Identifiant (ID) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 29419 | Mayo stage IIIa | Nathalie Meuleman | Amyloidose | Caelum Biosciences, Inc. | CAEL101-302 | Trial closed for recruitment | A Phase 3, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of CAEL-101 and Plasma Cell Dyscrasia Treatment Versus Placebo and Plasma Cell Dyscrasia Treatment in Plasma Cell Dyscrasia Treatment-Naïve Patients with Mayo Stage IIIa AL Amyloidosis | nathalie.meuleman@hubruxelles.be | 3 | 3 | |
| 29417 | Smoldering myeloma defined by IMWG 2014 criteria Diagnosed less than 1 year before the inclusion |
Nathalie Meuleman | Myeloma | IFM | CARRISMM | Trial closed for recruitment | Evaluation of the impact of the update multiple myeloma criteria on the natural history of smoldering myeloma in order to establish new recommendations about follow-up and prognostic evaluation of smoldering myeloma | nathalie.meuleman@hubruxelles.be | |||
| 22643 | 2nd to 4th line / at least 1 bi-dimensionaly measurable lesion/ HbA1c <= 8,5% at screening | Marie Maerevoet | Non-Hodgkin lymphoma | Bayer | CHRONOS-4 | Trial closed for recruitment | A Phase III, randomized, double-blind, controlled, multicenter study of intravenous PI3K inhibitor copanlisib in combination with standard immunochemotherapy versus standard immunochemotherapy in patients with relapsed indolent non-Hodgkin's lymphoma (iNHL) | marie.maerevoet@hubruxelles.be | 3 | 3 | |
| 22673 | MCL - at least 1 but no more than 3 prior systemic treatment regimens | Marie Maerevoet | Non-Hodgkin lymphoma | Incyte Corporate | CITADEL-205 | Trial closed | A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3Kdelta Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor (CITADEL-205) | marie.maerevoet@hubruxelles.be | 2 | 2 | |
| 29424 | Participants who have histologically documented FL or DLBCL, that has relapsed or failed to respond to at least two prior systemic treatment regimens, that expresses CD20 as determined by the local laboratory, at least one bi-dimensionally measurable (?1. | Marie Maerevoet | Non-Hodgkin lymphoma | F. Hoffmann-La Roche Ltd | CO43116 | Trial closed | A phase Ib/II open-label, multicenter study evaluating the safety, efficacy, and pharmacokinetics of Mosunetuzumab in combination with Tiragolumab with or without Atezolizumab in patients with relapsed or refractory b-cell non-hodgkin lymphoma | marie.maerevoet@hubruxelles.be | 1/2 | 1 | |
| 22637 | newly diagnosed multiple myeloma >= 70 years old |
Nathalie Meuleman | Myeloma | UZ-K.U.Leuven | COMPASS | Trial closed | COMPASS study - Comparison of different geriatric screening methods in newly diagnosed multiple myeloma patients, and assessment of therapeutic efficacy and toxicity in fit and frail patients. A multicenter observational Belgian study | nathalie.meuleman@hubruxelles.be | |||
| 29677 | - Histologically proven DLBCL and associated subtypes - Relapsed or refractory disease after first-line chemoimmunotherapy - Participants must have received adequate first-line therapy containing at least the combination of an anthracycline-based regime |
Marie Maerevoet | Non-Hodgkin lymphoma | Miltenyi Biomedicine GmbH | DALY 2-EU | Trial open for recruitment | A pivotal Phase II randomised, multi-centre, open-label study to evaluate the efficacy and safety of MB-CART2019.1 compared to standard of care therapy in participants with relapsed/refractory diffuse large B-cell lymphoma (R-R DLBCL), who are not eligible for high-dose chemotherapy and autologous stem cell transplantation (M-2020-371) | marie.maerevoet@hubruxelles.be | 2 | 2 | |
| 22691 | any line | Philippe Lewalle | Multiple | Celyad | DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy with NKR-2 | Trial closed | An open-label, Phase I study to assess the safety of NKR-2 treatment administration after a non-myeloablative preconditioning chemotherapy in relapse/refractory acute myeloid leukemia or myelodysplastic syndrome patients | philippe.lewalle@hubruxelles.be | 1 | 1 | |
| 22692 | any line / Lung metastasis | Konstantinos Stathopoulos | Lung | EORTC | EORTC 1658 | Trial closed | Qualification of imaging methods to assess cancer drug induced interstitial lung disease (ImageILD) | konstantinos.stathopoulos@hubruxelles.be | |||
| 28585 | 1st line - DLBCL, transformed, follicular NHL grade IIIb | Marie Maerevoet | Non-Hodgkin lymphoma | Lysarc | Epi-RCHOP | Trial open for recruitment | A Phase Ib-II Study of tazemetostat (EPZ-6438) in newly diagnosed Diffuse Large B Cell Lymphoma (DLBCL) or high risk Follicular Lymphoma (FL) patients treated by R-CHOP | marie.maerevoet@hubruxelles.be | 1/2 | 1 | |
| 22798 | Relasped/refractory patient | Christiane Jungels | Multiple | Imcheck | EVICTION | Trial open for recruitment | A fist-in-human, two-part, open-label, clinical study to assess the safety, tolerability and activity of intravenous doses of ICT01 as monotherapy and in combination with an Immune Checkpoint Inhibitor, in patients with advanced-stage, relapsed/refractory cancer | christiane.jungels@hubruxelles.be | 1 | 1 | |
| 28922 | Relapse or Refractory Diffuse Large B-cell Lymphoma CD20+ DLBCL, Failed previous HDT-ASCT or not eligible for HDT-ASCT. ECOG PS score 0-2 Acceptable renal and liver function Patient must have detectable disease by PET scan and by CT scan or MRI. |
Marie Maerevoet | Non-Hodgkin lymphoma | Genmab | GCT3013-05 | Trial closed | A Randomized, Open-Label, Phase 3 Trial of Epocoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma | marie.maerevoet@hubruxelles.be | 3 | 3 | |
| 22672 | >=65 years old or, 18 to 64 years old and have at least 1 of the following: 1) CIRS score >6 or 2) Creatinine clearance estimated <70 mL/min - At least one lymph node >1.5 cm by CT - Absence of del 17p or TP53 mutation |
Dominique Bron | LLC | Janssen | GLOW | Trial closed for recruitment | Randomized, Open-label, Phase 3 study of the Combination of Ibrutinib plus Venetoclax versus Chlorambucil plus Obinutuzumab for the First-line Treatment of Subjects with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | dominique.bron@hubruxelles.be | 3 | 3 | |
| 29413 | blood and bone marrow exploration mandatory before steroids prephase /ALL B Phi negative, ALL B Phi positive, and ALL T eligible | Sebastian Wittnebel | Acute leukemia | APHP | GRAALL-2014 trial | Trial closed | Multicenter trial for the treatment of Acute Lymhoblastic Leukemia (ALL) in younger adults (18-59 years) (GRAALL-2014 trial) | Sebastian.Wittnebel@hubruxelles.be | 2/3 | 2 |